Winston Patrick Kuo

Vision: Bring the best hospital to every community and bring the best doctor to every home Mission: Empower the global healthcare ecosystem through innovation Predicine a global molecular insights company that is committed to advancing precision medicine in oncology and infectious diseases. Predicine has developed a proprietary cell-free DNA- and cell-free RNA-based liquid biopsy technology enabling minimally invasive molecular diagnosis for treatment selection, therapy monitoring, and minimal residual disease and early cancer detection. The company has launched a portfolio of blood-, urine- and tissue-based molecular diagnostic assays for oncology and infectious diseases. Through its business operations in US-EU-APAC-China, Predicine partners with leading biopharma companies, institutions, and governments to support personalized healthcare on a global scale. Predicine operates in CLIA and CAP certified facilities in US (Silicon Valley, Chicago, Houston) and China (Shanghai) with business offices in Singapore, Berlin, Boston, Tustin, Beijing, Suzhou and Harbin. Currently, Predicine partners with leading biopharma companies and hospitals to support patient testing, clinical trials and CDx development in US, China, EU, Japan, Australia, among others. http://www.predicine.com Predicine, Care for Life!

Predicine, a CLIA/CAP certified lab expanded its infrastructure and services to provide COVID-19 testing solutions to the Bay Area. Testing options included RT-PCR, NGS, antigen and IgM/IgG antibody tests. Flexible collections - clinic visits, on-site and At-Home solutions. Currently providing tests for travelers, schools, nursing homes, urgent care centers, businesses and many more. https://testing.covid19.ca.gov/covid-19-testing-task-force-laboratory-list/

The American Culture and International Innovation Cooperation Center is committed to the development of international cultural and business exchanges and promotes the development of international education.

The Westchester Biotech Project Initiatives is a nonprofit association for researchers, engineers, and data scientists. Throughout the year we bring our community together through symposia, webinars, roundtables, committees, and boards. Building upon the history developed through the Westchester Biotech Project , our goal is to enhance the research and development process, with a focus upon supporting scientists as collaborators throughout their careers. http://biopharmaresearchinitiatives.org/

Exosomics Siena SpA is a leading innovative Company performing applied research and R&D activities in the field of exosome associated biomarkers, with a specific focus on the development and validation of proprietary immunometric multiplex assays for non-invasive cancer diagnostics and monitoring and point of care devices for cancer screening. We also develop arrays for companion diagnostics in collaboration for pharma companies. http://www.exosomics.eu/sab.jsp

HansaBioMed OU is an innovative company performing research and development in the field of Exosome Sciences. Its mission is to consolidate and maintain the worldwide leadership in production and commercialization of kits, reagents, equipment and services dedicated to exosome research for the Life Science market. HansaBioMed develops, produces and commercializes a wide range of products dedicated to the expanding market of exosome research, which are essential tools for all scientists engaged in this rapidly growing field of science. The best known of HansaBioMed owned brands is the ExoTESTTM platform, a proprietary immune-based solution to capture, quantify and characterize exosomes from biological fluids. http://www.hansabiomed.eu/index.php/component/content/article?id=3:partnering

The BioPharma Research Council (BRC) is an independent, nonprofit organization founded in 2009 to support the broad community of scientists and business professionals in the biopharmaceutical space. By addressing scientists who are making and developing discoveries throughout the biotech/pharmaceutical pipeline, we provide an environment for interaction that can lead to better communication, enhanced collaboration, and faster, more effective medical progress. http://www.biopharmaresearchcouncil.org/scientific-advisory-board/

Genomic Expression has developed a clinically applicable, platform-agnostic sample preparation method for Next Generation Sequencing: an intelligent baitfree target filtering technology, applicable for highly complex and quantitative analysis such as RNA. The product is a kit with buffers and enzymes together with a bioinformatics tool that can be used with existing installed instruments without any modification to the instruments. In addition, they have access to the Danish health care system, which includes the largest biobank in the world, linked to electronic medical records that were established a decade ago, provide a superior hypothesis-free platform that transforms biomarker discovery from a fishing expedition into a math exercise capable of delivering proof of concept of RNA diagnostic in 1 month for $1M. This represent a paradigm shift that will save at least $20 million between 2 to 5 years of development time in the development of Next Generation Diagnostics.

The Helix Bioscience Institute was designed as the next generation not-for-profit innovation accelerator optimally leveraging the virtual with the brick and mortar. The institute will serve to enable researchers to conduct transformative directed discovery and translational research employing a vast array of tools and resources. The desired outcome is to drive innovation that directly bridges discovery to pre-clinical. http://www.helixbioscience.org/about-us/

http://www.qnrf.org/en-us/

Health Science and Technology (HST) program